Navigation Links
Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
Date:6/23/2009

CHARLOTTESVILLE, Virginia, June 23 /PRNewswire/ -- Biovista Inc. today announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model of temporal lobe epilepsy. BVA-601, an existing drug that Biovista repositioned in epilepsy, exhibits both anti-epileptic and neuroprotective activity. In this pre-clinical trial, BVA-601 induced a statistically significant decrease of epileptic activity in mice pre-treated with Kainic acid.

"We are pleased with these initial results that confirm the predicted efficacy of BVA-601 and encourage us to further test and develop this compound in a disease area where there is a need for new, patient-friendly therapies," said Aris Persidis, Ph.D., President of Biovista. "This successful repositioning builds on our previously reported success with BVA-101 in multiple sclerosis, expanding our CNS portfolio. At the present time we are exploring all options available to us, including the further co-development with a pharmaceutical company and the licensing of the IP to a generics company," added Dr. Persidis.

For a non-confidential information pack on BVA-601, contact Biovista at info@biovista.com.

About Biovista's BVA-601 trial in the Kainic acid model of epilepsy

Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures may be transient signs and/or symptoms due to abnormal, excessive or synchronous neuronal activity in the brain. Epilepsy is one of the world's oldest recognized conditions, affecting around 50 million people worldwide. Fear, discrimination and social stigma have surrounded epilepsy for centuries. Some of the stigma continues today in many countries impacting the quality of life of people with the
'/>"/>

SOURCE Biovista Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Dragon Pharma Announces Results of 2009 Annual General Meeting
4. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
5. Isolagen, Inc. Announces Receipt of Interim Order from Bankruptcy Court Approving DIP Motion
6. Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
7. Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities
8. Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center
9. Shamir Optical Industry Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website
10. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
11. Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... EpiVax, Inc. today announced a collaborative r... RHHBY) aimed at evaluating EpiVax’s proprie... reduce detrimental immune responses to certain dr...on, the EpiVax Tregitope technology will be evalua...ein therapeutics. , (Vocu...
(Date:12/1/2009)...LIS and NORTH VANCOUVER, British Columbia, Dec. 1 ...wholly owned subsidiary of The Dow Chemical Compan...oday announced the signing of a research and comme...ides Dow AgroSciences with access to Agrisoma,s pr...n an exclusive basis in major food crops, and on a...
(Date:12/1/2009)... DNA Genotek, a leading provider of products fo...at Tepnel Pharmaceutical Services will offer Orage...nucleic acid extraction and genotyping service. ,...er 1, 2009 -- DNA Genotek , a leading provider of...announced that Tepnel Pharmaceutical Services wi...
(Date:12/1/2009)... Michael R. Drapp, a 34-year veteran of the hig...Technologies, a business development and intellect...rging nanotechnology space. The company also plan... nanotechnology incubator. , ...ael R. Drapp , a 34-year veteran of the high-techn...
Breaking Biology Technology:EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology 2EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology 3Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops 2Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops 3Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 2Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 4
...ICK, Mass. and SAN DIEGO, May 28 Boston,Scientifi...daq: CRYO ) today,announced that Boston Scientifi...ansaction follows the definitive agreement announc..., all remaining outstanding CryoCor,shares are ent...tal of,approximately $17.6 million. CryoCor is now...
...LADELPHIA, May 28 Premier Research Group plc (AIM...group, announces the,appointment of Anthony Faraga...edical Management and Safety. In this position, Dr...t and Safety team ensuring the delivery of,quality...s to Premier Research a wealth of experience in,gl...
...nvited Oral Presentation by Dr. John St. John -, ...particle Technology -, ADDISON, Texas, May 28 UL... upcoming 8th World Biomaterials Congress, to be,h.... John St. John, ULURU,s,Vice President of Materia...along with the presentation of three posters., Th...
Other Biology Technology:Boston Scientific Completes Acquisition of CryoCor 2Boston Scientific Completes Acquisition of CryoCor 3Premier Research Names Anthony Faragasso, MD as Executive Director and Global Head of Medical Management and Safety 2ULURU Inc. to Present at the 8th World Biomaterials Congress 2ULURU Inc. to Present at the 8th World Biomaterials Congress 3
(Date:12/1/2009)...en,t just for listening to the radio anymore. They...ices. Research from North Carolina State Universit...creating shape-shifting antennas that open the doo...lic safety to military deployment. , Modern ante...re are limitations to how far they can be bent an...
(Date:11/30/2009)...prehensive review of the state of Antarctica,s cli...stem is published this week (Tuesday 1 December) b...SCAR). The review - Antarctic Climate Change and ... the icy continent, identifies areas for future sc...ons that policy makers have about Antarctic meltin...
(Date:11/30/2009)...entists from The Forsyth Institute, the University...sworth Center, have used state-of-the-art technolo...onema pallidum, the bacterium which causes syphili...e bacteria can now be shown in three dimensions. T...and reveals previously unknown features, which may...
Breaking Biology News(10 mins):Shape shifters: Researchers create new breed of antennas 2First comprehensive review of the state of Antarctica's climate 2Scientists gain new understanding of disease-causing bacteria 2Novo Nordisk is Changing Possibilities in Hemophilia 5875 1Novo Nordisk is Changing Possibilities in Hemophilia 5875 2Novo Nordisk is Changing Possibilities in Hemophilia 5875 3Warner Chilcott Completes Acquisition of P 26amp 3BGs Global Branded Prescription Pharmaceuticals Business 5871 1Warner Chilcott Completes Acquisition of P 26amp 3BGs Global Branded Prescription Pharmaceuticals Business 5871 2Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 5867 1Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 5867 2Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 5867 3
...lished in the international journal Neurobiology ...eing physically fit helps the brain function at th...for Medical Research Senior Scholar, Poulin finds ...brain, and, as a result, cognitive abilities. , "...r stroke and dementia," says Poulin, a scientist i...
... drought and flood come in rapid succession, the e...n the sequence of those events, according to a new... The study, which focused on tree species common t...maintained higher growth rates and were less likel...d, rather than vice versa. The findings could have...
...rsity study published in the Journal of Neuroscie... sexual ones, are conveyed in human sweat. , Deni..., looked at how the brains of female volunteers pr... men. The results of the experiment indicated the ...ding human sexual sweat. , Scientists have long k...
Other Biology News:Research finds older women who are more physically fit have better cognitive function 2Sequence matters in droughts and floods 2
Rabbit Anti-CHIP Polyclonal Antibody, Unconjugated from Abcam
Tall Shaker Stand, Holds 1 Stacking Shaker from Thermo Scientific
...rings together two mature, well-understood technol...ized capture surfaces. This combination produces a...tion of molecular binding events without the use o...ure molecules are immobilized on the dotLab Sensor...
Heparin Clotting Assay Kit, HEPTEST from AMERICAN DIAGNOSTICA
Biology Products: